Coronavirus company news summary - Pharmed and MyBio make Covid-19 rapid antigen self-test available in Ireland - LightDeck Diagnostics awarded $35.1m for Covid-19 tests - Verdict Medical Devices
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Coronavirus company news summary – Pharmed and MyBio make Covid-19 rapid antigen self-test available in Ireland – LightDeck Diagnostics awarded $35.1m for Covid-19 tests

09 Jul 2021

MyBio, Irish-based life sciences company, has partnered with Pharmed, a pharmacies supplier in the UK and Ireland, to bring an accurate and convenient Covid-19 rapid antigen self-test to their pharmacies nationwide. The MP Biomedicals Covid-19 Rapid Antigen self-test is the first European produced, an EU-certified rapid antigen self-test that delivers results in just 15 mins with 98.72% accuracy. The test is expected to curb the spread of the Delta variant in Ireland and will also enable them to issue EU digital travel certificates to customers.

Global WholeHealth Partners, a biotechnology company offering in vitro diagnostic point-of-care tests, says the antibody IgG/IgM tests it offers are capable of detecting all the SARS-CoV-2 variants. The Alpha, Beta and Gamma strains contain multiple mutations, most prevalent in the S gene, which encodes the spike protein. Global WholeHealth Partners also says its tests reveal quicker results and can be reviewed more quickly by frontline healthcare workers.

The US Department of Defence (DOD), on behalf and in coordination with the Department of Health and Human Services (HHS), has awarded a $35.1m contract to LightDeck Diagnostics, a biotechnology company offering low-cost diagnostic tests, to increase the manufacturing of its upcoming ultra-rapid Covid-19 Ultra-Rapid Antigen and Total Antibody tests. LightDeck will utilise the funds to increase its Colorado-based production capacity, from 50,000 tests per month to one million per month by September 2022.